These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 9430357)

  • 1. Absence of anti-envelope antibodies and clearance of hepatitis C virus in a cohort of Irish women infected in 1977.
    Grellier L; Brown D; Power J; Dusheiko G
    J Viral Hepat; 1997; 4(6):379-81. PubMed ID: 9430357
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of antibody to hepatitis C virus E2 recombinant antigen among samples indeterminate for anti-HCV after wide serological testing and correlation with viremia. The Spanish Study Group for Blood Donors at Risk of Transmission of HCV.
    León P; López JA; Elola C; Domingo CJ; Echevarria JM
    Vox Sang; 1996; 70(4):213-6. PubMed ID: 9123926
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of Hepatitis C Virus Core and E2 antigenic recombinant proteins and their use for development of diagnostic assays.
    Ali A; Nisar M; Idrees M; Rafique S; Iqbal M
    Int J Infect Dis; 2015 May; 34():84-9. PubMed ID: 25796431
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of differential antibody production against hepatitis C virus in different HCV infection status.
    Rafik M; Bakr S; Soliman D; Mohammed N; Ragab D; ElHady WA; Samir N
    Virol J; 2016 Jun; 13():116. PubMed ID: 27357382
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunologic events during the incubation period of hepatitis C virus infection: the role of antibodies to E2 glycoprotein. Multicentre Hemodialysis Cohort Study on Viral Hepatitis.
    Psichogiou M; Katsoulidou A; Vaindirli E; Francis B; Lee SR; Hatzakis A
    Transfusion; 1997 Aug; 37(8):858-62. PubMed ID: 9280333
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of the E2 Hypervariable Region (HVR1) in the Immunogenicity of a Recombinant Hepatitis C Virus Vaccine.
    Law JLM; Logan M; Wong J; Kundu J; Hockman D; Landi A; Chen C; Crawford K; Wininger M; Johnson J; Mesa Prince C; Dudek E; Mehta N; Tyrrell DL; Houghton M
    J Virol; 2018 Jun; 92(11):. PubMed ID: 29540595
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatitis C virus infection in dialysis and chronic liver patients: Viraemia dependent anti-E2-antibody response.
    Hanuka N; Sikuler E; Tovbin D; Neville L; Nussbaum O; Mostoslavsky M; Orgel M; Yaari A; Manor S; Dagan S; Hilzenrat N; Shemer-Avni Y
    J Med Virol; 2004 Aug; 73(4):529-35. PubMed ID: 15221896
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sequential changes of hepatitis C virus antibody profiles during treatment of chronic hepatitis C of genotype 1b: pretreatment antibody response to E2/NS1 correlated sustained response.
    Chu CM; Sheen IS; Liaw YF
    Infection; 2004 Jun; 32(3):153-6. PubMed ID: 15188075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heterogeneity of the humoral anti-HCV/E2 response in persistently infected patients as demonstrated by divergent patterns of inhibition of the binding of anti-HCV/E2 human monoclonal antibodies.
    Mancini N; Canducci F; Carletti S; Berardinelli E; Serafini G; Grieco A; Perotti M; Malcangi G; Danieli MG; Varaldo PE; Clementi M; Burioni R
    J Biol Regul Homeost Agents; 2003; 17(2):183-7. PubMed ID: 14518720
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical significance of hepatitis C viral RNA status and its correlation to antibodies to structural HCV antigens in anti-HCV reactive patients with normal liver tests.
    Fong TL; Lee SR; Briggs WK; Valinluck B; Govindarajan S; Hoffman A; Jaczko B; Redeker AG
    J Med Virol; 1996 Jul; 49(3):253-8. PubMed ID: 8818974
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibody responses to hepatitis C envelope proteins in patients with acute or chronic hepatitis C.
    Fournillier-Jacob A; Lunel F; Cahour A; Cresta P; Frangeul L; Perrin M; Girard M; Wychowski C
    J Med Virol; 1996 Oct; 50(2):159-67. PubMed ID: 8915882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A quantitative test to estimate neutralizing antibodies to the hepatitis C virus: cytofluorimetric assessment of envelope glycoprotein 2 binding to target cells.
    Rosa D; Campagnoli S; Moretto C; Guenzi E; Cousens L; Chin M; Dong C; Weiner AJ; Lau JY; Choo QL; Chien D; Pileri P; Houghton M; Abrignani S
    Proc Natl Acad Sci U S A; 1996 Mar; 93(5):1759-63. PubMed ID: 8700831
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monitoring antibody titers to recombinant Core-NS3 fusion polypeptide is useful for evaluating hepatitis C virus infection and responses to interferon-alpha therapy.
    Park YM; Byun BH; Choi JY; Bae SH; Kim BS; So HS; Ryu WS
    J Korean Med Sci; 1999 Apr; 14(2):165-70. PubMed ID: 10331562
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Significance of IgM anti-HCV core level in chronic hepatitis C.
    Papatheodoridis GV; Delladetsima JK; Katsoulidou A; Sypsa V; Albrecht M; Michel G; Hatzakis A; Tassopoulos NC
    J Hepatol; 1997 Jul; 27(1):36-41. PubMed ID: 9252071
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cross-reactivity and clinical impact of the antibody response to hepatitis C virus second envelope glycoprotein (E2).
    Hadlock KG; Gish R; Rowe J; Rajyaguru SS; Newsom M; Warford A; Foung SK
    J Med Virol; 2001 Sep; 65(1):23-9. PubMed ID: 11505439
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modulation of epitope-specific anti-hepatitis C virus E2 (anti-HCV/E2) antibodies by anti-viral treatment.
    Mancini N; Carletti S; Perotti M; Romanò L; Craxì RD; Craxì A; Zanetti AR; Clementi M; Burioni R
    J Med Virol; 2006 Oct; 78(10):1304-11. PubMed ID: 16927283
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The hepatitis C virus glycan shield and evasion of the humoral immune response.
    Helle F; Duverlie G; Dubuisson J
    Viruses; 2011 Oct; 3(10):1909-32. PubMed ID: 22069522
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of the antibody reactivity to synthetic peptides from different parts of the hepatitis C virus genome.
    Pujol FH; Khudyakov YE; Devesa M; León G; Blitz-Dorfman L; Monsalve F; Lambert SB; Kalinina TY; Liprandi F; Fields HA
    Viral Immunol; 1996; 9(2):89-96. PubMed ID: 8822625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-envelope 1 and 2 immune response in chronic hepatitis C patients: effects of hepatitis B virus co-infection and interferon treatment.
    Zampino R; Marrone A; Durante Mangoni E; Santarpia L; Sica A; Tripodi MF; Utili R; Ruggiero G; Adinolfi LE
    J Med Virol; 2004 May; 73(1):33-7. PubMed ID: 15042645
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterisation of a panel of monoclonal antibodies raised against recombinant HCV core protein.
    Ferns RB; Tuke PW; Sweenie CH
    J Med Virol; 1996 Nov; 50(3):221-9. PubMed ID: 8923286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.